Avidity Partners Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Avidity Partners Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-94,000	Closed	-$7.62M	–	84
2025 Q1	$7.62M	Buy	+94,000	New	+$8.4M	1.45%	26
2022 Q4	–	Sell	-1,480,000	Closed	-$120M	–	105
2022 Q3	$117M	Sell	1,480,000 -395,000	-21%	-$33.3M	2.39%	11
2022 Q2	$139M	Buy	1,875,000 +1,435,000	+326%	+$108M	3.2%	13
2022 Q1	$39.5M	Buy	+440,000	New	+$40.6M	0.82%	36

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Avidity Partners Management's XBI Position: Q2 2025 in Review

Avidity Partners Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 94,000 shares — an estimated $7.62M sold.

Avidity Partners Management first reported a position in XBI in Q1 2022 and held it in 4 quarters. The position peaked at $139M in Q2 2022. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

Avidity Partners Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
Avidity Partners Management sold 94,000 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $7.62M.
Avidity Partners Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 4 quarters.
Avidity Partners Management's State Street SPDR S&P Biotech ETF position peaked at $139M in Q2 2022.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.